Last reviewed · How we verify

Jemincare — Portfolio Competitive Intelligence Brief

Jemincare pipeline: 1 marketed, 0 filed, 3 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 6 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sonidegib Phosphate Capsules Sonidegib Phosphate Capsules marketed Hedgehog pathway inhibitor Smoothened (SMO) Oncology
JMKX001899 JMKX001899 phase 3 S1P1 receptor modulator S1P1 Immunology
JYB1904 JYB1904 phase 3 S1P1 receptor antagonist S1P1 Autoimmune diseases
Placebo+JYB1904 Placebo+JYB1904 phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 2 shared drug classes
  2. Pfizer · 2 shared drug classes
  3. Archigen Biotech Limited · 1 shared drug class
  4. BioLineRx, Ltd. · 1 shared drug class
  5. Bright Minds Biosciences Pty Ltd · 1 shared drug class
  6. Celtic Pharma Development Services · 1 shared drug class
  7. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jemincare:

Cite this brief

Drug Landscape (2026). Jemincare — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jemincare. Accessed 2026-05-14.

Related